Iatrogenic Cerebral Amyloid Angiopaty Post Neurosurgery:Frequency, Clinical Profile, Radiological Features, and Outcome
Stroke 54:1214-1223, 1224, Kaushik,K.,et al, 2023
Intracerebral Haemorrhage Caused by Iatrogenic Cerebral Amyloid Angiopathy in a Patient with a History of Neurosurgery 35 Years Earlier
Lancet 402:11, Fandler-Hofler,et al, 2023
Blook Transfusion and Brain Amyloidosis, Should We Be Worried?
JAMA 330:921-922, Greenberg,S.M., 2023
Clinicopathologic Conference, Fat Embolism Syndrome
NEJM 385:2464-2474, Case 39-2021, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Facial Nerve Marginal Mandibular Branch Lesion
Neurol 94:e2069-e2071, Fleuren, K. & Staals, J., 2020
A Misdiagnosis of Atypical Trigeminal Neuralgia
Neurol 93:124-131, Duvall, J.R. & Robertson, C.E., 2019
Management of Anticoagulants in Patients Undergoing Endoscopic Procedure
www.UptoDate.com, Dec, Kamath, P.S., 2018
Candida Infections of the Central Nervous System
UptoDate Jan, Kauffman, C.A., 2016
Cystic Lesions as a Rare Complication of Deep Brain Stimulation
Mov Disord Clin Pract 3:87-90, Sharma, V.D.,et al, 2016
Ischemic Optic Neuropathies
NEJM 372:2428-2436, Biousse, V. & Newman, N.J., 2015
Tension Pneumocephalus after Facial Surgery
BMJ 346:f536, Foley, C.,et al, 2013
Summary of Evidence-Based Guideline: Periprocedural Management of Antithrombic Medications in Patients with Ischemic Cerebrovascular Disease
Neurol 80:2065-2069, Armstrong, M.,et al, 2013
Tumefactive MS Lesions under Fingolimod
Neurol 81:1654-1658, Pilz, G.,et al, 2013
Left Atrial Catheter Ablation and Ischemic Stroke
Stroke 43:265-270, Haeusler, K.G.,et al, 2012
Recovery after Spinal Cord Infarcts
Neurol 78:114-121, Robertson,C.E.,et al, 2012
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012
Management of Anticoagulation Before and After Elective Surgery
www.uptodate.com Dec. 2012, Lip, G. & Douketis, J., 2012
Spectrum of Neurologic Complications in Chronic Lymphocytic Leukemia
Clin Lymphoma Myeloma Leuk 12:164-179, Lopes da Silva, R., 2012
Pediatric Sciatic Neuropathies: A 30-year Prospective Study
Neurol 76:976-979, Srinivasan,J.,et al, 2011
Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients
NEJM 364:2187-98, 2256, Smith, C.R.,et al, 2011
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
Management and Outcome of CSF-JC Virus PCR-negative PML in a Natalizumab-treated Patient with MS
Neurol 77:2010-2016, Kuhle, J.,et al, 2011
Predicting Postoperative Hydrocephalus in 227 Patients with Skull Base Meningioma
Neurosurg Focus 30:E9, 1-7, Burkhardt,J-K.,et al, 2011
Saphenous Mononeuropathy After Popliteal Vein Aneurysm Repair
Neurologist 16:47-49, Shenoy,A. &Wiesman,J., 2010
In-Hospital Complication Rates After Stent Treatment of 388 Symptomatic Intracranial Stenoses: Results from the INTRASTENT Multicentric Registry
Stroke 41:494-498, Kurre,W.,et al, 2010
Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the Causal Factors and Can It be Avoided?
Arch Neurol 67:923-930, Warnke,C., et al, 2010
Cardiotoxicity and Other Adverse Events Associated With Mitoxantrone Treatment for MS
Neurol 74:1822-1826, Kingwell,E., et al, 2010
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009
PML-IRIS in Patients with HIV Infection: Clinical Manifestations and Treatment with Steroids
Neurol 72:1458-1464,1454, Tan,K.,et al, 2009
Memantine Induces Reversible Neurologic Impairment in Patients with MS
Neurol 72:1630-1633, Villoslada,P.,et al, 2009
Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009
Postwithdrawal Rebound Increase in T2 Lesional Activity in Natalizumab-Treated MS Patients
Neurol 70:1150-1151,1073, Vellinga,M.M.,et al, 2008
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
4-Aminopyridine Toxicity with Unintentional Overdose in Four Patients with Multiple Sclerosis
Neurol 71:1833-1834, Burton,J.M.,et al, 2008
Symptomatic Intracranial Stenosis:Cerebrovascular Complications from Elective Stent Placement
Radiology 243:188-197, Jiang,W-J.,et al, 2007
Pathological Gambling after Bilateral Subthalamic Nucleus Stimulation in Parkinson Disease
JNNP 78:517-519, Smeding,H.M.M.,et al, 2007
Neurologic Complications of Gastric Bypass Surgery for Morbid Obesity
Neurol 68:1843-1850, Juhasz-Pocsine,K.,et al, 2007
Natalizumab for Multiple Sclerosis
NEJM 356:2622-2629, Ransohoff,R.M., 2007
Visual Loss After Povidone-Iodine Pleurodesis
NEJM 357:1264-1265, Khuri,F.R., 2007
Panic and Fear Induced by Deep Brain Stimulation
JNNP 77:410-412, Shapira,HN.A.,et al, 2006
Post-operative aspergillosis
Clin Microbiol Infect 12:1060-1076, Pasqualotto, A.C. & Denning, D.W., 2006
FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005
Patent Foramen Ovale Closure Devices
JAMA 294:366-369, Maisel,W.H.&Laskey,W.K., 2005
Surgical and Hardware Complications of Subthalamic Stimulation
Neurol 63:612-616, Lyons,K.E.,et al, 2004
Incidence and Clinical Course of Thrombus Formation on Atrial Septal Defect and Patent Foramen Ovale Closure Devices in 1,000 Consecutive Patients
J Am Coll Cardiol 43:302-309, Krumsdorf,U.,et al, 2004
Incidence of Thrombus Formation on the CardioSEAL and the Amplatzer Interatrial Closure Devices
Am J Cardiol 93:426-431, Anzai,H.,et al, 2004
Paraplegia After Ligation of Esophageal Varices
Neurol 60:879, Debette,S.,et al, 2003